Pharmaceutical

NMPA approves BBM and Takeda China’s haemophilia B therapy

Belief BioMed (BBM) and Takeda China have announced the receipt of China’s NMPA approval for BBM-H901for treating haemophilia B

Apr 12, 2025 - 06:00
NMPA approves BBM and Takeda China’s haemophilia B therapy
Belief BioMed (BBM) and Takeda China have announced the receipt of China’s NMPA approval for BBM-H901for treating haemophilia B
Read the original article

Tags:

Previous Article

AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use

Next Article

Can AI replace medical writers? Experts say not immediately

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Morning Rounds: Our newsroom’s favorite stories of 2023

Morning Rounds: Our newsroom’s favorite stories of 2023

Dec 23, 2023

Signal: Abortion pill restriction may drive more patients to off-label drug

Signal: Abortion pill restriction may drive more patien...

Aug 18, 2023

Opinion: Former Surgeon General Jerome Adams: Prioritize new antivirals for Covid

Opinion: Former Surgeon General Jerome Adams: Prioritiz...

Jun 22, 2023